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Abstract 
 
Atrial fibrillation (AF) is associated with structural, electrical and contractile remodeling of 
the atria. Development and progression of atrial fibrosis is the hallmark of structural 
remodeling in AF and is considered to be substrate for AF perpetuation. In contrast, 
experimental and clinical data on impact of ventricular fibrotic processes in pathogenesis of 
AF and its complications are controversial. Ventricular fibrosis appears to contribute to 
abnormalities in cardiac relaxation and contractility, and development of heart failure, a 
common finding in AF. Given the frequent coexistence of AF and heart failure and the fact 
that both conditions affect patient prognosis better understanding of mutual impact of fibrosis 
in AF and heart failure is of particular interest. In this review article, we provide an overview 
on the general mechanisms of cardiac fibrosis in AF, differences between fibrotic processes 
in atria and ventricles, and the clinical and prognostic significance of cardiac fibrosis in AF. 
 
Key words: atrial fibrillation, heart failure, cardiac fibrosis 
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List of abbreviations 
 
AF, atrial fibrillation 
CTGF, connective tissue growth factor 
DE-CMR, delayed enhancement cardiac magnetic resonance imaging  
ECM, extracellular matrix 
ET-1, endothelin-1 
HF, heart failure 
miR, microribonucleic acid 
MMP, matrix metalloproteinase 
PDGF, platelet-derived growth factor 
TGF-β1, transforming growth factor β1 
TIMP, tissue inhibitor of matrix metalloproteinase 
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Introduction 
 
Mechanisms of AF are complex and associated with structural and electrical remodeling in 
the atria and ventricular myocardium. The key electrophysiological mechanisms of AF 
include (i) focal firing due to triggered activity (early and delayed after-depolarisations); (ii) 
multiple re-entries due to shortening of action potential and (iii) heterogeneity of impulse 
conduction caused by atrial fibrosis. Development and progression of atrial fibrosis is the 
hallmark of structural remodeling in AF and is considered to be the substrate for AF 
perpetuation. Advanced atrial fibrosis is associated with more frequent paroxysms of AF, 
transformation of arrhythmia into a permanent type and reduced effectiveness of 
antiarrhythmic drug therapy (1,2).  
 
Despite a large body of experimental and clinical evidence supporting role of atrial fibrosis in 
AF, data on the fibrotic processes in ventricles in patients with AF are limited. The available 
data indicate that ventricular fibrosis may be at least partly responsible for impaired cardiac 
relaxation and contractility seen in many AF patients. Cardiac fibrosis may be implicated in 
complex interactions between AF and heart failure (HF), both of which can be cause(s) and 
consequence(s) of each other. Given the high frequency of coexistence of both AF and heart 
failure, and their clear prognostic significance (e.g., increased risk of hospitalization or death 
related to heart failure deterioration) a better understanding of role of cardiac fibrosis in 
pathogenesis of AF and its complications is important (3). This review focuses on general 
mechanisms of the cardiac fibrosis in AF, differences between fibrotic processes in atria and 
ventricles and on clinical and prognostic impact of cardiac fibrosis in AF. 
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Mechanisms of cardiac fibrosis 
 
Progressive accumulation of fibrotic tissue in myocardium is one of the major components of 
cardiac remodeling. Formation and re-distribution of connective tissue fibers modulates 
myocardial geometry in order to adapt to new conditions of (patho)physiological functioning 
and to prevent or minimize effects of new mechanical, chemical and electrical stimuli. This 
adaptation process involves both cellular components of myocardium and extracellular matrix 
(ECM), an acellular component of the heart, containing a variety of fibers with predominance 
of collagen (4). 
 
However, excessive ECM production in adults is commonly associated with pathogenesis of 
cardiovascular diseases, resulting in abnormalities of cardiac contraction and relaxation thus 
inevitably leading to HF (5). Whilst in the healthy heart collagen deposition is restricted to 
maintenance of heart architecture, in the process of progression of various cardiac disorders 
the collagen network undergoes quantitative and qualitative changes leading to excessive 
accumulation of collagen either in the regions of cardiomyocyte loss (e.g., in myocardial 
infarction, reparative fibrosis) or diffusely in the myocardium not involved in the focal injury 
(e.g., in dilated cardiomyopathy, reactive fibrosis) (4,5). 
 
Cardiac fibroblasts and myofibroblasts 
 
Both cellular and extracellular components take part in the remodeling process. Cardiac 
fibroblasts play a pivotal role in formation of the ECM. They are numerous within the 
myocardium and can account up to 60% of cells in the cardiac muscle (6). Thus cardiac Ре
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fibroblasts even outnumber cardiomyocytes although the latter cells largely determine total 
myocardial mass. 
 
The population of cardiac fibroblast in healthy adult hearts is maintained at a relatively low 
level being predominantly represented by resident fibroblasts and epithelial cells subjected to 
epithelial-to-mesenchymal transition. In pathological conditions, numbers of fibroblasts 
dramatically increase via differentiation from several cell lineages, including monocytes, 
endothelial cells, bone marrow circulating progenitor cells and pericytes (7-9). 
 
The physiologic functions of fibroblasts extend beyond metabolism of the ECM. Tight 
connections between the fibroblasts, fibers of the ECM and other cellular components form 
multidimensional network acting as an integral sensor of dynamic changes in the various 
mechanical, chemical and electrical stimuli in the myocardium. In response to these stimuli, 
this complex system adjusts extracellular matrix turnover, regulates cardiomyocyte 
hypertrophy and to a smaller extent cardiomyocyte proliferation, but it also triggers activation 
of fibrotic and inflammatory pathways. Of note, cardiac fibroblasts are able to exhibit various 
phenotypes depending on the surrounding microenvironment (10). 
 
Cardiac fibroblasts also contribute to electrical remodeling in AF due to their different 
electrophysiological properties compared to surrounding cardiomyocytes. Fibroblasts are 
essentially nonexcitable cells but they can transfer currents between cardiomyocytes via 
connexins. This may result in heterogeneity of current conduction, shortening of action 
potentials, depolarization of resting cardiomyocytes, and induction of spontaneous phase 4 
depolarization (11). Consequently, fibroblasts may be directly involved in re-entry 
occurrence and perpetuation. Interestingly, computer modeling myofibroblast proliferation in Ре
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AF and their electrical interaction with cardiomyocytes were found to be sufficient for re-
entry formation even in absence of fibrosis (12). 
 
Myofibroblasts is a group of cells that play a particular significant role in cardiac fibrosis. 
Myofibroblasts derive from cardiac fibroblasts but they have approximately two-fold higher 
capacity to synthesize collagen. In comparison to cardiac fibroblasts, myofibroblasts do not 
appear in healthy myocardium, they are more responsive to proinflammatory and profibrotic 
stimuli, and are capable of synthesis of a large variety of cytokines and chemokines (13). 
Importantly, myofibroblasts contain α-smooth muscle actin and adhesion complex 
(fibronexus). The latter binds myofibroblast internal microfilaments to ECM proteins that 
helps to provide contractile force to the surrounding extracellular matrix . 
 
ECM turnover and cardiac fibroblast activity are regulated by a range of growth factors, 
cytokines, and hormones as well as by mechanical stretch and hypoxia. These factors 
determine fibroblast gene expression, their differentiation and intensity of collagen synthesis.  
 
TGF-β1 signaling  
 
Amongst the numerous regulatory factors, angiotensin II and transforming growth factor 
(TGF)-β1 (Figure 1) are the most potent stimulators of collagen synthesis by cardiac 
fibroblasts (14,15). TGF-β1 produces its effects via binding to TGF-β1 dimerized receptor in 
the extracellular space, which consists of two receptors – TβRI and TβRII. Ligand-receptor 
binding results in the cascade of reactions of phosphorylation during which inactive Smad 
proteins 2, 3 and 4 form Smad complex (16). 
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The Smad complex then translocates to the nuclei of the target cells where it regulates 
expression of genes involved in fibrogenesis via appropriate regulatory regions, for example, 
CTGF and periostin.(17,18) This results into production of so-called matricellular protein, a 
pro-fibrotic protein secreted into the extracellular matrix. The matricellular protein modulates 
intercellular and cell-to-matrix interactions that further stimulate extracellular matrix protein 
synthesis but are not directly involved in ECM structure and mechanical organization or 
differentiation of cardiac fibroblasts into myofibroblasts (19). 
 
TGF-β-activated kinase 1 (TAK1) is an alternative to Smad pathway for TGF-β1-induced 
fibrosis. TAK1 is a member of the mitogen-activated protein kinase (MAPK) family (20). 
Importantly, apart from activation of fibroblast and collagen synthesis TGF-β1 can also 
induce apoptosis of cardiomyocytes (21). 
 
Of note, angiotensin II is not able to induce cardiac hypertrophy and fibrosis in the absence of 
TGF-β1, but it up-regulates TGF-β1 synthesis, Smad2 phosphorylation, nuclear translocation 
of the Smad complex and increases Smad DNA-binding activity. TGF-β1 in turn can directly 
stimulate expression of angiotensin II type 1 receptor (22). Angiotensin II also predisposes to 
fibrosis by promoting expression of pro-fibrotic factors, such as endothelin-1. In conjunction 
with aldosterone angiotensin II promotes oxidative stress (i.e. excess production of reactive 
oxygen species) and inflammation, mainly by activation of NADPH oxidase (23,24). 
 
Matrix metalloproteases and tissue inhibitors of matrix metalloproteases 
 
Remodeling and maintenance of the extracellular space includes not only synthesis but also 
coordinated degradation of the extracellular matrix proteins. Matrix metalloproteases (MMP) Ре
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and their tissue inhibitors, synthesized by cardiomyocytes and cardiac fibroblasts are 
intimately involved in maintenance of the extracellular matrix homeostasis (25). Indeed, 
MMP expression increases in a time-dependent manner with left ventricular dysfunction and 
dilatation (26). Overexpression of MMP-1 has been observed to cause compensatory 
hypertrophy and increased collagen concentration within the myocardium. In contrast, 
targeted deletion of MMP-2 results in amelioration of left ventricular remodeling (27). Not 
surprisingly MMP activity increases in line with TGF-β1 expression within the myocardium 
and correlates with the level of inflammation and oxidative stress (28). 
 
Furthermore, collagen and matrix fragments produced by the action of MMP-1 themselves 
form bioactive molecules, so called matrikines, and release ECM-embedded pro-
inflammatory and pro-fibrotic factors. They promote fibroblast activation and transition to a 
myofibroblast phenotype and effectively stimulate connective tissue synthesis by serving as 
ligands of leucocyte integrins and other cell activating receptors (25,29). The latter explains 
progression of fibrosis when high MMPs activity despite the primary MMP function directed 
towards matrix degradation. MMP activity is regulated via TIMPs and reversion-inducing-
cysteine-rich protein with Kazal motifs (RECK). RECK overexpression was found to blunt 
angiotensin II-induced MMP activation and cardiac fibroblast migration (30). 
 
Regulatory role of microribonucleic acids 
 
Nuclear miRs play important regulatory roles in cardiac remodeling (31). They are referred to 
as endogenous, single stranded, short (approximately 22 nucleotides), noncoding RNAs. 
MiRs degrade or inhibit at the post-transcriptional level the translation of their target 
messenger RNAs, thus regulating gene expression (32).  Ре
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Several miRs are involved in the fibrogenesis. miR-133 and miR-30 regulate cardiac fibrosis 
by repressing CTGF expression. They were found to be down-regulated in left ventricular 
hypertrophy that was associated with increased CTGF expression (33). miR-133 knockout 
mice developed advanced fibrosis and heart failure with predisposition to sudden death (34). 
On the contrary overexpression of miR-133 results in decreased collagen synthesis by 
fibroblasts, reduced myocardial fibrosis and apoptosis (33,35). miR-21 is involved in up-
regulation of one of the pro-fibrotic pathways (ERK) and promotes MMP-2 expression 
(36,37). Interestingly, it also produces protective effects, including defense against oxidative 
stress, inhibition of pro-apoptotic factors and increased expression of anti-apoptotic genes 
(38). Finally, miR-29 is associated with the collagen type I and III deposition. Upregulation 
of miR-29 leads to downregulation of these proteins and vice versa (39). 
 
Inflammation  
 
AF is common in patients with overt inflammatory states of cardiac and noncardiac location 
(e.g., myocarditis, pericarditis, pneumonia, inflammatory bowel disease), but low grade 
subclinical inflammation (e.g., in coronary heart disease) also contributes to pathogenesis of 
the arrhythmia (Figure 2) (40). Whether AF is a cause or consequence of the inflammatory 
process, the latter is related to oxidative stress perpetuated by myocardial infiltration with 
inflammatory cells (e.g., macrophages) and release of reactive oxygen species by cells of the 
ECM. Inflammation is further exacerbated by activation of renin-angiotensin-aldosterone 
system followed by activation of NADPH oxidase. These processes consequently trigger 
TGF-β1 signaling, structural and electrical remodeling (41). Various inflammatory cytokines 
and chemokines, such as interleukins 1 and 6, tumor necrosis factor α, monocyte Ре
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chemoattractant protein 1, are upregulated in AF and linked to progression from paroxysmal 
to chronic AF and AF recurrence post-cardioversion (40). 
 
Inflammation plays a particular role in postoperative AF (e.g., after CABG, valvular 
replacement surgery) and post catheter ablation. In a recent meta-analysis of 925 
postoperative patients serum C-reactive protein was a potent predictor of new-onset AF (42). 
Similarly, a meta-analysis of 7 studies of post-ablation patients confirmed predictive role of 
C-reactive protein for AF recurrence (43). 
 
Aging and cardiac fibrosis 
 
Prevalence of AF significantly increases in the elderly. Cardiac aging is a complex process 
featured by progressive decline in heart functions and ventricular and atrial remodeling. This 
process includes reduction in cardiomyocyte numbers, hypertrophy of the remaining 
cardiomyocytes, alteration of myofibrillar orientation, proliferation of cardiac fibroblasts, and 
collagen deposition. Progressive fibrosis is a hallmark of aging heart as confirmed by 
increased collagen volume fraction in myocardium and imaging in animal and human studies 
(44). 
 
Age-related cardiac fibrosis reflects multiple processes that accompany cardiac senescence, 
chronic activation of the renin-angiotensin-aldosterone axis, excessive β-adrenergic and 
endothelin signaling, activation of TGF-β1 pathway, disruption in intracellular calcium 
homeostasis, cardiomyocyte apoptosis, recruitment of mononuclear cells and fibroblast 
progenitors, downregulation of mitochondrial NAD-dependent deacetylase sirtuin-1 (45). 
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Increased generation of reactive oxygen species and diminished antioxidant capacity are 
major contributors to age-related myocardial remodeling (Figure 3). Oxidative molecules 
derive from oxidative phosphorylation processes in mitochondria, increased NADPH oxidase 
activity, uncoupled nitric oxide synthase function, lipid oxidation within peroxisomes, and 
upregulation of cyclooxygenases and xanthine oxidase (46). Chronic oxidative stress leads to 
persistence of low-grade inflammation thus further accelerating cardiac fibrosis. Among 
important regulators of aging-related processes is miR-34a with PNUTS (also known as 
PPP1R10) being the target. Ageing-induced expression of miR-34a and inhibition of PNUTS 
is associated with telomere shortening, DNA damage, cardiomyocyte apoptosis, and impaired 
functional recovery after ischemic injury (47). Hence, profibrotic mechanisms involved in AF 
pathogenesis are clearly enhanced by aging. 
 
Cardiomyocytes – cardiac fibroblasts communication 
 
Close interaction between cardiomyocytes and cardiac (myo)fibroblasts is essential for their 
function. These interactions are facilitated by multiple paracrine signals including those 
predisposing to fibrosis (Figure 4). Cardiomyocytes, cardiac fibroblasts, and myofibroblasts 
share many common molecular pathways (e.g., mediated by angiotensin II, TGF-β1, 
endothelin, cytokines). However response to signaling may vary depending on cell type: 
hypertrophy and reduced cell survival of cardiomyocytes are promoted by angiotensin II–
induced release of TGF-β1 and endothelin-1 from fibroblasts while angiotensin II was also 
found to trigger release TGF-β1 and endothelin-1 from cardiomyocytes and to stimulate 
fibroblasts proliferation, their differentiation to myofibroblast phenotype and synthesis of 
components of ECM.(48) Greater proliferation of fibroblasts was observed around Ре
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cardiomyocytes expressing AT1 receptors compared to cells with knocked-out AT1 gene 
(49).  
 
There are also differences between the cells in receptor density and receptor kinase activity, 
which may interfere with final effect of effector molecules. For example, fibroblasts are 
known to carry more receptors to angiotensin II then cardiomyocytes (49). Multiple other 
regulatory substances are implicated in fibroblast-cardiomyocyte interplay (e.g., fibroblast 
growth factor 2, interleukins, natriuretic peptides, and miR) (48). Some stimuli are attributed 
predominantly to fibroblasts (e.g. PDGF, FGF-2, activation by mechanical stretching) while 
abnormalities in calcium handling are largely seen in cardiomyocytes (50). 
 
Cardiac remodeling requires fibrosis as an essential part, and is a complex process that also 
incorporates multiple other pathways, such as hypoxia signaling, 
osteoprotegerin/RANK/RANKL axis and Ca signaling among others. Detailed description of 
these pathways is beyond the scope of the current review. 
 
In summary, ECM represents macromolecular metabolically active dynamic network of 
fibers (predominantly collagen) and cells (predominantly cardiac fibroblasts with a capacity 
to differentiate into myofibroblasts) that is essential for normal heart functioning. Cellular 
component of the extracellular matrix is linked to the fibrillar one and, hence, is capable to 
respond to mechanical stretch and stress as well as to a variety of autocrine and paracrine 
stimuli by change in their proliferation, migration and intensity of collagen synthesis. These 
processes may have unfavorable role in cardiac remodeling and the pathogenesis of 
cardiovascular diseases. 
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Atrial fibrosis in atrial fibrillation 
 
A variety of signaling systems are involved in promotion of atrial fibrosis as evidenced by 
numerous human and animal data (Tables 1-2). Atrial fibrosis may develop as part of AF-
related structural remodeling as well as consequence of other cardiovascular diseases, which 
result in atrial overload and stretch. Conditions associated with atrial fibrosis include 
hypertension, valvular heart disease and HF, and they cause broadly similar histologic 
changes in atrial myocardium (51). However, the precise causality between AF and atrial 
fibrosis may be difficult to establish. 
 
Experimental data also yielded controversial results. For example, some models of atrial 
tachyarrhythmia demonstrated marked biatrial dilation with changes in atrial architecture and 
myocyte characteristics, such as loss of myofibrils, accumulation of glycogen, changes in 
mitochondrial number, shape and size, fragmentation of sarcoplasmic reticulum, dispersion 
of nuclear chromatin whilst the interstitial space remained unaltered without evidence of 
increased connective tissue content (52). In contrast, more recent studies of rapid atrial 
pacing demonstrated upregulation of potent profibrotic factors as angiotensin II and TGF-β1 
(53) and increased collagen content in the atrial interstitium (54). The discrepancy might be 
attributable to the time required for development of detectable fibrosis after initiation of 
profibrotic pathways. For example, in a mice model of heart failure at 8 weeks there were no 
signs of histological fibrosis in the left atrium despite increased expression of genes related to 
fibrosis (55). This discrepancy can also suggest existence of still poorly understood 
mechanisms of inhibition of fibrosis despite activation of profibrotic genes. 
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Background cardiovascular disease causing HF can be associated with more advanced atrial 
changes. For example a model produced by combination of rapid atrial pacing with mitral 
regurgitation, inevitably resulted in intercellular space expansion in the left atrium and AF 
(56). This observation is consistent with a HF model of AF caused by ventricular tachypacing 
where connective tissue contained increased numbers of fibroblasts, more collagen, and 
showed signs of degeneration and necrosis in comparison to atrial pacing model (57). In a 
study by Cardin et al ventricular tachypacing led to approximately 10-fold overexpression of 
collagen mRNA in atrial cardiomyocytes, in comparison to atrial pacing noted as early as at 
24 hours and progressing further at 2 weeks. Of note, 8 collagen genes were upregulated 
more than 10-fold, fibrillin 8-fold and MMP2 4.5-fold at 2 weeks but there were no changes 
in their expression at 24 hours (58). Also, TGF-β1 levels in failing hearts in animals appeared 
to be higher than in the non-failing heart (59). Although development of atrial fibrosis has 
been well documented in several animal models of AF associated with HF the cardiac fibrosis 
is unlikely to be the sole mechanism of HF, including HFpEF. For instance, predominant 
electrical remodeling with minimal if any evidence of atrial fibrosis and preservation of 
ventricular contractility was seen in a sheep model of prolonged persistent AF induced by 
intermittent atrial tachypacing, but no significant tachycardia during the observation period 
(60). 
 
Thus, atrial remodeling is the mainstay for initiation and perpetuation of AF. Atrial structural 
and functional changes may develop as a result of underlying cardiac conditions, pathological 
systemic processes, or AF itself. Atrial remodeling also commonly occurs as part of age-
related processes. However, relationship between AF course and atrial fibrosis is complex 
and nonlinear, meaning that higher collagen deposition within the atria does not always cause 
more frequent paroxysms of the arrhythmia and its progression towards persistent or Ре
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permanent type. Plethora of mechanisms (hemodynamic alterations, mechanical stretching, 
changes in hormones, growth factors, proinflammatory cytokines, etc.) modulates severity of 
atrial fibrosis. A large body of experimental and clinical data has already provided insights 
into key mechanisms of atrial fibrosis. 
 
Extracardiac and the genetic factors contributing to atrial fibrosis 
  
Multiple ‘non-cardiac’ factors predispose to fibrosis in AF, including obesity, metabolic 
syndrome, use of toxic substances, athlete heart, obstructive sleep apnea, systemic 
inflammation, and thyrotoxicosis. Ultimately all these factors affect the myocardium (61). 
Recently diabetes, a disease associated with specific cardiomyopathy and excessive cardiac 
fibrosis was shown to triple risk of AF in obese individuals (62). Obesity leads to electrical 
and structural atrial remodeling and is associated with diastolic ventricular impairment, atral 
dilatation and myocardial lipidosis (63). Obesity in AF is related to delay and significant 
heterogeneity in atrial conduction, atrial inflammatory infiltration and interstitial fibrosis. 
Pathways underlying these changes include activation TGF-β1 signaling, oxidative stress, 
upregulation of PDGF and endothelin (64). Pericardial fat envelope could produce 
constriction effect thus disturbing cardiac relaxation. Some adipokines have clearly 
profibrotic properties (e.g. activin A, a member of TGF-β1 superfamily), whilst AF itself 
affects adipocyte-related gene expression facilitating expansion of cardiac fat (65). 
 
Obstructive and central sleep apnea are also associated with atrial remodeling and AF (66). 
Animal models obstructive sleep apnea showed substantial connexin-43 downregulation, 
altered expression of channel proteins with net effects of shortening of atrial refractory 
period, slowing of atrial conduction, cardiomyocyte apoptosis and cardiac fibrosis. Repeated Ре
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apnea episodes associated with chronic hypoxia trigger production of strongly profibrotic 
hypoxia-inducible factors 1α and 2α (67). Moreover, such patients have increased 
angiotensin-converting enzyme and IL-6 expression with inhibited degradation of atrial 
collagen via MMP-2 (68). Also sleep apnea leads to myocardial hypertrophy and diastolic 
dysfunction, thus further potentiating development of HF in presence of AF (69,70). There 
are multiple other factors contributing to atrial remodeling and chronic low-grade 
inflammation with increased propensity to AF (e.g. chronic kidney disease, diabetes) (11). 
 
AF has a genetic predisposition. The genetic background of AF is complex with multiple 
pathways involved. In ‘lone’ AF, i.e. in the absence of apparent cardiovascular disease, 
histological and imaging evidence suggests similar extent of atrial fibrosis as in AF patients 
with structural heart disease.(71) A specific fibrotic atrial cardiomyopathy as an underlying 
condition predisposing to AF development and persistence has been suggested and it is likely 
to have genetic background.(72,73). One of genes involved in the atrial development is the 
PITX2 gene. PITX2 deficiency results in formation of enlarged atrial with thin walls and 
prominent deficiency in expression of ion channels (74). AF is also related to polymorphisms 
in genes involved in fibrotic pathways, such as genes responsible for modulation of synthesis 
of interleukins 1 and 6 (2). Nonetheless robust evidence on target genes directly responsible 
for AF related cardiac fibrosis is lacking at present with further research warranted in this 
direction. 
 
Ventricular fibrosis in atrial fibrillation 
 
Association of AF with ventricular fibrosis is less established than for atrial fibrosis. 
Ventricular fibrotic changes are more pronounced in AF patients than in subjects with sinus Ре
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rhythm, both with magnetic resonance or ultrasound imaging (75,76). Also more extensive 
changes were found in patients with permanent or persistent arrhythmia compared to 
paroxysmal AF (75-77). These reports were confirmed by animal data showing implication of 
ventricular fibrosis in cardiac remodeling and rate control in AF (78). Avitall et al observed 
more extensive ventricular fibrosis in AF when ventricles were not protected from high atrial 
rate with the atrioventricular node ablation than in the ablated animals (79). 
 
Atrial and ventricular fibrosis in AF are likely to share many common mechanisms, although 
extent of the changes may vary between the two parts of the heart. In transgenic mice with 
TGF-β1 overexpression TGF-β1 upregulation was more pronounced in atria than in 
ventricles. High TGF-β1 levels were associated with enhanced expression of only two 
profibrotic genes in ventricles in contrast to 80 genes in the atria. Interestingly, TβRI, TβRII 
and Smad protein levels were similar in ventricles and atria, but Smad2 phosphorylation was 
increased in atria only, making them prone to development of selective fibrosis (59). Several 
have been suggested as mechanisms for different effects of TGF-β1 in ventricles versus atria 
(Table 3) (59). Importantly, the processes above were reported in intact ventricles. In case of 
combination of TGF-β1 overexpression with other pathophysiological stimuli (such as those 
seen in HF), TGF-β1 mediated profibrotic ventricular effects appear to be enhanced, although 
atrial fibrosis still predominated (59). Also, atrial fibroblasts have been found to be more 
susceptible to PDGF, angiotensin II and endothelin 1 indicating that their activity was 
premodulated by local atrial factors (80). There is a differential impact of hemodynamic 
changes (e.g., stretch) and the precise biochemical processes on fibroblast activity in 
ventricles and atria remain unclear at present. 
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In summary, the cardiac profibrotic microenvironment in AF is unlikely to be strictly isolated 
by the atria, and ventricular myocardium is likely to be affected as well. Even within atrial 
myocardium fibrotic changes take years to become detectable with currently available 
diagnostic methods. With considerably higher myocardial thickness of the ventricles 
compared to atria detectable ventricular fibrosis may require prolonged time to develop 
unless it is amplified by co-existing pathological conditions such as hypertension, coronary 
artery disease and heart failure. 
 
Imaging of cardiac fibrosis 
 
Significant technological advances allow more possibilities for characterization and 
quantification of focal and diffuse cardiac fibrosis, which was only possible with biopsy in 
the past. The most commonly used late (delayed) gadolinium enhancement cardiac magnetic 
resonance (DE-CMR) imaging is based on difference in properties of healthy myocardium 
and areas of fibrotic tissue to clear gadolinium, that is T1 relaxation time shortening agent. 
Fibrotic tissue is characterized by slowing of gadolinium washing-out resulting in greater 
signal compared to surrounding ‘reference’ tissue. The latter, however, poses a problem of 
finding appropriate ‘reference’ tissue for quantification of diffuse cardiac fibrosis (81,82). 
 
Another CMR-based method, T1 mapping was developed to overcome the problem. T1 
mapping is a calculation of a post-contrast myocardial T1 time by imaging a given plane with 
sequentially increasing inversion times without the need to compare the results to a normal 
reference tissue before or after the use of a contrast agent. This allows demonstration of 
diffuse fibrotic fibers with might appear nearly isointense using delayed enhancement.(81,82) 
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Despite being the gold standard CMR is not widely available. Hence echocardiography 
remains an alternative for evaluation of cardiac fibrosis based on dependency of acoustic 
properties on myocardial composition. Collagen causes ultrasound scattering and attenuation, 
which can be measured as integrated backscatter (83). Furthermore, with the 
echocardiography functional assessment as strain peak and strain velocity - parameters which 
characterize reservoir performance and were found to predict the degree of fibrosis detected 
in histological specimens and via CMR (84,85). 
 
Clinical implications and prognostic impacts of atrial fibrosis 
 
Atrial remodeling including excessive fibrosis has major clinical implication in AF. 
Numerous studies link more extensive atrial interstitial fibrosis to lower effectiveness of AF 
catheter ablation and MAZE procedure, increased risk of development of postoperative AF 
and impaired postprocedural recovery of atrial function (Table 4). Interestingly, delayed 
enhancement of atrial myocardium is helpful for evaluation of post-ablation atrial fibrosis and 
its relation to left atrial reverse remodeling on sinus rhythm (86). Patients undergoing 
pulmonary vein isolation had higher AF recurrence rate with a lesser degree of left atrial and 
pulmonary vein scarring on DE-CMR (87). 
 
There are limited data on association of atrial fibrosis with stroke risk in AF patients. An 
association was found between percentage of atrial fibrosis assessed via DE-CMR and higher 
CHADS2 score and stroke history (88). Moreover, in their population (387 patients, 36 
strokes) adding left atrial fibrosis to the risk model (i.e. CHADS2, but not accounting for 
previous stroke due to retrospective nature of the study) improved the c-statistic form 0.58 to 
0.72. This was consistent with another study which demonstrated better prediction of left Ре
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atrial thrombosis or spontaneous echocardiographic contrast by addition of the degree of 
atrial fibrosis to either the CHADS2 or CHA2DS2-VASc scores (89). However routine use of 
expensive and not universally available DE-CMR for stroke prediction is not practical at 
present in comparison with available and recommended stroke risk assessment tools, and the 
approach clearly needs further validation. 
Galectin–3 involved in regulation of fibrosis was found to be associated with the LA volume 
index and AF (OR 87.5, 95% CI 6.1-1265) and, also, to be significantly higher in patients 
with persistent AF then in those with paroxysmal type of arrhythmia (90). 
 
Clinical implications and prognostic impact of ventricular fibrosis 
 
Ventricular fibrosis has detrimental impact on both systolic function (due to replacement of 
apoptotic and necrotized myocardium) and diastolic function (due to increasing stiffness and 
decreasing compliance) (14). This makes the ventricular fibrosis relevant both in the context 
of heart failure with preserved or reduced ejection fraction.  
Although scarce data are available on histological assessment of ventricular myocardial 
fibrosis in patients with AF small case series of ventricular biopsies suggest presence of 
active myocarditis or nonspecific necrotic/fibrotic changes in patients with ‘lone’ AF (91). It 
is likely that most of ‘lone’ AF cases have, in fact, background myocardial pathology, which 
cannot be easily determined using routine tests and its is reflective of primary electrical 
disturbances and subclinical cardiomyopathies, likely associated with myocardial fibrosis. 
 
Contemporary markers of ventricular fibrosis (e.g., beta-galactoside-binding lectin galectin-
3) are studied increasingly in patients with HF and they have shown predictive value for Ре
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adverse outcomes but specific relevance in the context of AF remained to be established 
(92,93). 
 
Prognostic significance of markers of collagen turnover, was assessed in hypertensive heart 
disease, hypertrophic cardiomyopathy and HF (94,95). However, the major limitation of 
blood markers of collagen turnover is that they are not cardiac-specific and may not 
accurately reflect myocardial collagen content. Hence, the results are often conflicting, 
depending largely on selection of study cohorts (e.g., exclusion of patients with hepatic and 
kidney dysfunction, pulmonary fibrosis, osteoporosis, metastatic bone disease, etc. or 
measuring cardiac gradient of collagen markers (i.e., blood from coronary sinus vs. systemic 
circulation) (96). 
 
It is even more problematic or even impossible to distinguish atrial and ventricular 
contribution to circulating levels of byproducts of collagen synthesis and degradation. 
Consequently attribution of elevated markers of collagen turnover to AF-related atrial fibrosis 
alone might be not entirely correct. 
 
For example, in the I-PRESERVE trial collagen substudy that included 29% of AF patients 
procollagen type I amino-terminal peptide and procollagen type III amino-terminal peptide 
were predictive of all-cause mortality and cardiovascular hospitalizations, but this association 
lost significance after adjustment for other confounders (97). 
 
Similarly, majority of imaging-based studies on evaluation of ventricular fibrosis focused on 
patients with arterial hypertension, dilated and hypertrophic cardiomyopathy, HF, but only 
few directly addressed AF patients. Moreover, those few studies with AF included mostly Ре
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patients referred for AF ablation, which is currently indicated for patients with paroxysmal or 
persistent arrhythmia resistant to antiarrhythmic treatment. Thus, these studies may not be 
representative of the whole AF population. 
 
Recently Neilan et al revealed association between the presence (HR 5.08, 95% CI 3.08-8.36) 
and extent (HR 1.15, 95% CI 1.10-1.21) of left ventricular late gadolinium enhancement on 
magnetic resonance imaging and all-cause mortality (n=664, median follow-up 42 months, 
mean LVEF 56±10%) (98). The observed associations were even stronger when patients with 
the evidence is ischemic heart disease were excluded from analysis (98). The major limitation 
of this study was inclusion of patients selected for AF ablation with a median duration of 
arrhythmia since onset of 50 days.  
 
Another study that involved patients with arterial hypertension and longer AF duration 
(median of 37 months) and based on CMR T1 mapping found the left ventricular 
extracellular to be independently predictive of AF recurrence as well as of the composite end 
point of AF recurrence, admission with HF, and death (HR 1.35, 95% CI 1.21-1.51).(99) 
Prognostic value of diffuse ventricular fibrosis for AF recurrence after ablation procedure 
was further confirmed by McLellan et al with a cut off level of postcontrast ventricular T1 
time <380 ms being related to better outcome (100). In a small cohort of patients without left 
ventricular fibrosis as evidenced by the absence of late gadolinium enhancement on CMR in 
patients with systolic HF significant improvement of left ventricular function was observed 
after AF catheter ablation. However the study had no comparator group with established 
ventricular fibrosis to assess impact of sinus rhythm restoration (101). 
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Thus far, similarly to atrial fibrosis it is unclear whether AF is a trigger of the present 
profibrotic pathways in the left ventricle or merely a marker of preexisting fibrotic changes, 
or even both. 
 
Treatment approaches to reduce cardiac fibrosis  
 
Given that angiotensin II is a potent stimulator of profibrotic pathways, angiotensin-
converting enzyme inhibitors, angiotensin receptor antagonists and mineralcorticoid receptor 
antagonists deemed to reduce fibrosis progression. This was, in fact, supported by several 
animal studies, but not by clinical trials, so far. Retrospective analyses and meta-analyses of 
randomized trials showed inconclusive results both for primary and secondary AF prevention. 
It has been also accepted that overall primary prevention of AF with these agents is more 
feasible then than the secondary prevention as myocardial fibrosis is more likely to be slowed 
down than reversed (102,103).  
 
Therefore inhibitors of angiotensin axis are only recommended for AF management when the 
arrhythmia is associated with other underlying conditions associated with myocardial fibrotic 
remodeling such as arterial hypertension with left ventricular hypertrophy, systolic HF and 
they are not recommended in patients without apparent cardiovascular disease (e.g., ‘lone’ 
AF) (104). 
 
Many other components of profibrotic cardiac pathways (e.g., TGF-β1, PDGF, etc.) represent 
attractive therapeutic targets. Their suppression with either antibody blockade or 
oligonucleotide interference was shown to reduce interstitial fibrosis in animal experiments. Ре
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Nonetheless experience from the animal data need to be confirmed by clinical trials and 
better understanding of details of fibrotic pathways is required.(15) 
 
Conclusion 
 
AF is associated with fibrotic processes both in atria and ventricles. Despite common pro-
fibrotic pathways, signaling in ventricular and supraventricular parts of the heart seems to be 
different. Atrial fibrosis may precede development of AF, which in turn results in further 
progression of atrial remodeling. Structural heart disease appears to have greater impact on 
both atrial and ventricular fibrosis than arrhythmia per se but it allows persistent activation of 
pro-fibrotic stimuli. Whilst the role of atrial fibrosis in AF is well documented, the 
implication of ventricular fibrosis in pathogenesis and outcome of conditions associated with 
AF clearly requires further research. 
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Table 1. Studies on mechanisms of atrial fibrosis in atrial fibrillation in humans 
Reference Number 
(AF/SR) 
Sample 
tested 
LVEF, % 
(AF/controls) 
Results (AF vs. controls) Observed associations 
Adam et al, 
2010 (105) 
5/5 LAA 61±6/59±6 ↑collagen, CTGF, NADPHox, Rac1, N-cadherin, 
connexin 43, angiotensin II  
NA 
Adam et al, 
2012 (106) 
5/5 LAA 61±6/59±6 ↑miR-21 miR-21 with collagen, CTGF, Rac1, 
LOX, angiotensin II 
Cao et al, 2013 
(107) 
48/24 RAA 63±5 (paroxysmal), 
64±5 (persistent) / 64±3 
↑OPG, RANKL, RANK, RANKL/OPG ratio (In AF) OPG, RANKL, RANK, 
RANKL/OPG ratio with collagen type 
I, III 
Dawson et al, 
2013 (108) 
17/30* 
17/19 
Plasma 
RAA 
60±2/69±1 
 
↓miR-29b  
↓miR-29b in chronic AF 
NA 
Gramley et al, 
2007 (109) 
42/104 RAA 48±12 ↑collagen content, activity  
↔MMP2, MMP9 (mRNA and protein levels),  
↓PAI, TIMP1 and 2 (mRNA) with ↑ duration of AF  
NA 
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Gramley et al, 
2010 (67) 
42/116 RAA 50±11/47±12 ↑collagen content, HIF-1α, HIF-2α, VEGF, KDR, 
pKDR and microvessel density 
NA 
Gramley et al, 
2010 (110) 
61/102 RAA 48±11 ↑collagen content, early ↑ and later ↓ 
responsiveness to TGF-β1 with ↑ duration of AF: 
initially ↑TGF-β1 (mRNA and protein), TβRII, 
phSmad2, Smad4 (protein) followed by a ↓TβRI 
phSmad2 (protein) and ↑Smad7 (protein) 
NA 
Kallergis et al, 
2008 (111) 
70/20 Serum 60±4 (paroxysmal), 
56±9 (persistent)/60±5 
↑CITP, CICP, TIMP1 NA 
Ko et al, 2011 
(112) 
10/10 RAA 53±15/44±17 ↑collagen content, CTGF (protein and mRNA) NA 
Li et al, 2013 
(113) 
28/12 RA NA ↑collagen content, TGF-β1, Smad3 and CTGF TGF-β1, CTGF (mRNA and protein) 
with collagen content, TGF-β1, CTGF 
Mayyas et al, 
2010 (114) 
32/21 LAA 51±2/53±3 ↑ET-1 
↔ETAR or ETBR 
ET-1 with LA size, AF persistence 
Nishi et al, 16/13 RA 70±8 (unsuccessful ↑miR-21, miR-23b, miR-199b, miR-208b miR-21with collagen content 
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2013 (115) MAZE),  
53±15 (successful 
MAZE)/ 62.0±9 
Okumura et al, 
2011 (116) 
50/0 Serum NA ↓hsCRP, IL6, ANP, BNP 
↑MMP2, TIMP2, CITP during follow-up 
MMP-2 with AF recurrence  
Polyakova et 
al, 2008 (117) 
24/24 RA, 
RAA 
46±10/46±13 ↑collagen content, MMP2, MMP9, TIMP1, TIMP2, 
RECK, TGF-β1, Smad2 and phSmad2 
NA 
Qu et al, 2009 
(118) 
20/20 RA 51±15/63±14.63 ↑collagen content, TNFα, IL6 and NFκB activity NFκB activity with TNFα, IL6 and 
collagen content 
Rahmutula et 
al, 2013 (59) 
17/NA RA NA ↑TGβ1 and TGF-β1 signaling-related genes 
(phSmad2, Smad6, Ang II, etc.) 
NA 
Richter et al, 
2011 (119) 
30/0 Serum 62±2 ↑MMP9, TGF-β1, PIIINP after ablation PIIINP with AF recurrence;  
MMP9, TGF-β1 with ablation-induced 
LA volume reduction; 
MMP9 with RF energy on ablation 
Rudolph et al, 34/35 Plasma, 49±89/52±9 ↑MPO  NA 
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2010 (120) RAA 
Swartz et al, 
2012 (121) 
18/36 LAA, 
RAA, 
serum 
49±12/51±8 ↑collagen content, collagen type I, III, TGF-β1, Ang 
II (mRNA) 
↑PICP, PIIINP 
Collagen content with PICP 
Wang et al, 
2015 (122) 
30/17 LAA 63±7/70±4 ↑miR-146b-5p, MMP 9, collagen content; ↓TIMP-4 miR-146b-5p with TIMP-4 and 
collagen content 
Wilhelm et al, 
2006 (123) 
30/20 RAA NA ↔collagen content NA 
Wu et al, 2013 
(124) 
200/0 Plasma 53±10/57±6† NA TGF-β1 with AF recurrence 
Xi et al, 2013 
(125) 
83/52† RAA 62±6/30±5 ↔RANK, RANKL RANK, RANKL, RANKL/OPG ratio 
with collagen content 
Xie et al, 2013 
(126) 
22/15 LA, 55/60 ↑fibrocytes, collagen I and αSMA Fibrocytes with collagen content, LA 
volume index 
Xu et al, 2009 
(127) 
27/18 LA, RA 54±9/59±12 ↑collagen type I, MMP1 and MMP-9 (mRNA)  
↓TIMP1 (mRNA) 
Collagen type I (mRNA) with atrial 
diameter;  
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MMP1, MMP9 (mRNA) with TIMP1 
(mRNA) 
* Recurrent AF / nonrecurrent AF; † chronic AF / AF with subsequent SR recovery.  
↑, increased; ↓, reduced; ↔not changed; AF, atrial fibrillation; ANP, atrial natriuretic peptide; α-SMA, α-smooth muscle actin; BNP, brain 
natriuretic peptide; CICP, collagen type I C-terminal propeptide; C-terminal telopeptide CITP, collagen type I C-terminal telopeptide; COL1A1, 
gene encoding alpha-1 type I collagen; COL3A1, gene encoding alpha-1 type III collagen; CTGF, connective tissue growth factor; ET-1, 
endothelin-1; ETAR, type A ET-1 receptor; ETBR, type B ET-1 receptor; hsCRP, high sensitive C-reactive protein; HIF-1α, hypoxia-inducible 
factor 1α; HIF-2α, hypoxia-inducible factor 2α; IL-6, interleukin-6; KDR, VEGF receptor 2; LA, left atrium; LAA, left atrial appendage; LOX, 
lysyl oxidase; miR, microribonucleic acid; MMP, matrix metalloproteinase; MPO, myeloperoxidase; mRNA, messenger ribonucleic acid; NA, 
not available; NADPHox, nicotinamide adenine dinucleotide phosphate oxidase; NFκB, nuclear factor kappa B; OPG, osteoprotegerin; PICP, 
procollagen type I C-terminal propeptide;  PIIINP, procollagen type III N-terminal propeptide; PAI, plasminogen activation inhibitor; phSmad, 
phosphorylated Smad; pKDR, phosphorylated KDR; RA, right atrium; RAA, right atrial appendage; Rac1, Ras-related C3 botulinum toxin 
substrate 1; RANK, receptor activator of NFκB; RANKL, RANK ligand; RECK, reversion inducing cysteine-rich protein with Kazal motifs; 
Smad, transcriptional factor, named by fusion of C. elegans Sma protein and Drosophila Mad (mothers against decapentaplegic) protein, in 
reference to its sequence similarity to these proteins; TβRI, type I TGF-β1 receptor; TβRII, type II TGF-β1 receptor; TGF-β1, transforming 
growth factor beta 1; TIMP, tissue inhibitor of MMP; TNFα, tumor necrosis factor α; VEGF, vascular endothelial growth factor. 
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Table 2. Studies on mechanisms of atrial fibrosis in atrial fibrillation in animal experiments 
Reference Number 
(experiment/cont
rol) 
Samples tested Model Results (experiment vs. controls) 
Abed et al, 2013 (64) 30 LA, LAA, RA, and 
RAA  
High calorie diet ↑AF inducibiity, LA volume, collagen content, 
inflammatory infiltrates, lipidosis, ET-1, ETAR, ETBR, 
TGF-β1, PDGF with ↑ adiposity 
Adam et al, 2012 (106) NA LA Tx, Rac1 
overexpression 
↑collagen content, miR-21, spontaneous AF 
Cardin et al, 2012 (128) NA Myocardium Coronary artery ligation ↑miR-21, LA dilation and collagen content, AF 
inducibility 
Dawson et al, 2013 (108) 57/37 LA Ventricular 
tachypacing; Tx, miR-
29b knockout 
↓miR-29b, miR-133a, miR-133b;  
↑collagen content  
↑collagen content, COL1A1 (mRNA) 
He et al, 2011 (53) 8/8 LA Atrial tachypacing ↑Angiotensin II, TGF-β1, phSmad2/3, Arkadia, 
hydroxyproline expression;  
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↓Smad7 expression 
Kiryu et al, 2012 (129) 10/5 LA, RA Atrial tachypacing ↑CTGF, collagen type I, III;  
↔TGF-β1 
Ko et al, 2011 (112) 6/6 LA, RA Atrial tachypacing ↑Angiotensin II, CTGF (protein and mRNA) 
Li et al, 2012 (54) 21/21 LA Atrial tachypacing ↑collagen content, chronic inflammation;  
↓miR-133 and miR-30  
Rahmutula et al, 2013 
(59) 
15/15 Myocardium Tx, TGF-β1 
overexpression 
↑LA fibrosis, AF inducibility, TGF-β1 signaling-related 
genes in atria (TIMP, MMP, collagen, Smad2 or 3, TβRI 
and II) 
Rudolph et al, 2010 
(120) 
NA LA MPO knockout, 
angiotensin II 
pretreatment 
↓collagen content, MPO, MMP2, MMP9 and AF 
susceptibility 
Saba et al, 2005 (130) 32/37 Myocardium Tx, TNFα 
overexpression 
↑collagen content, AF inducibility 
Verheule et al, 2004 
(131) 
30/30 Myocardium Tx, TGF-β1 
overexpression 
↑LA fibrosis, AF inducibility 
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PDGF, platelet derived growth factor; Tx, transgenic; other abbreviations as in Table 1. 
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Table 3. Suggested mechanisms of predisposition of atrial versus ventricular myocardium to 
fibrosis 
Gene expression 
Higher expression of genes encoding extracellular matrix (e.g., fibronectin, laminin, fibulin), 
cell signaling (PDGF, PDGF receptor, angiopoietin, VEGF), etc. in fibroblasts 
Signaling pathways 
Greater signaling via canonical TGF-β1 pathway including  enhanced receptor binding, 
receptor-kinase activity, SMAD2/3 phosphorylation, reduced expression of the inhibitory 
SMAD7 in atrial myocytes with further stimulation of atrial fibroblasts 
Higher level of endogenous AT1 receptor and greater enhancement of receptor level 
following pathological influences 
Differential expression of adapter/scaffolding proteins (β-arrestin-1, G-proteins) involved in 
the  AT1 receptor-dependent aldosterone synthesis and secretion 
Higher expression of PAI1 
Cellular proliferation 
Higher myofibroblast density in healthy and diseased hearts with faster cell surface area 
being increased, distinct morphology at confluence and greater α-SMA and vimentin 
expression 
Higher proportion of fibroblasts in mitotic phases and displaying enhanced gene expression 
of fibroblast-selective markers 
Greater proliferation response of atrial fibroblasts for a range of growth factors (e.g., PDGF, 
angiotensin II, ET-1, and TGF-β1) 
AT1, angiotensin II receptor type 1; PAI-1, plasminogen activator inhibitor 1; other 
abbreviations as in Tables 1 to 2. Ре
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Table 4. Studies on prognostic significance of atrial fibrosis in AF patients 
References Number 
of 
patients 
Duration of 
follow-up 
Evaluation of atrial 
fibrosis 
Intervention Study outcome Association of atrial fibrosis 
and study outcome, OR or HR, 
95% CI 
Akoum et al, 
2011 (132) 
144 283±167 
days 
DE-MRI AF catheter ablation AF recurrence Increasing recurrence rate with 
increasing fibrosis degree 
Canpolat et al, 
2015 (133) 
41  18 months DE-MRI, TGF-β1 AF catheter ablation AF recurrence 1.127  
den Uijl et al, 
2011 (134) 
170 12±3 months IBS AF catheter ablation AF recurrence 2.80 (2.17-3.61) 
Ho et al, 2014 
(135) 
3306 10 years Galectin-3 NA Incident AF 1.19 (1.05-1.36)* 
Kainuma et al, 
2011 (136) 
24 NA Histology MAZE procedure, mitral 
valve surgery 
Unsuccessful MAZE 
procedure 
25.2 (1.1-567) 
Kallergis et al, 
2014 (137) 
164 2 months CITP DC cardioversion AF recurrence 3.25 
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Kawamura et al, 
2012 (138) 
142 2 years PIIINP Pharmacologic or DC 
cardioversion 
AF recurrence 2.63 (1.32–3.56) 
Kornej et al, 
2015 (139) 
119 6 months Galectin 3 AF catheter ablation AF recurrence Higher in AF patients but did 
not predict AF recurrence 
Kubota et al, 
2012 (140) 
27 3 years IBS None Progression from 
paroxysmal to persistent 
AF 
HR 8.74 for patients with IBS ≥ 
20 dB vs < 20 dB 
Kuppahally et 
al, 2010 (141) 
68 1 year DE-MRI AF catheter ablation AF recurrence 1.04 (1.01-1.08) 
Ling et al, 2014 
(142) 
132 1, 3, 6, 12, 
18, 24, 30 
months   
T1 mapping  AF catheter ablation AF recurrence 38% of AF recurrence in 
patients with T1 time <230 ms 
vs 25% in patients with T1 time 
>230 ms 
Malcolme-
Lawes et al, 
2013 (143) 
50 1 year DE-MRI AF catheter ablation AF recurrence Increasing recurrence rate with 
increasing fibrosis degree 
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Marrouche et al, 
2014 (144) 
272 475 days DE-MRI AF catheter ablation AF recurrence 1.06 (1.03-1.08) 
McGann et al, 
2014 (145) 
386 1 year DE-MRI AF catheter ablation AF recurrence 4.89 
Oakes et al, 
2009 (146) 
81 9.6±3.7 
months 
DE-MRI AF catheter ablation AF recurrence 4.88 (1.73–13.74) 
Olasinska-
Wisniewska, 
2012 (147) 
66 12 months Histology AF catheter ablation, mitral 
valve surgery 
AF recurrence 1.09 (1.012-1.17) 
Park et al, 2013 
(148) 
128 1 year TGF-β1 MAZE procedure Absence of atrial 
mechanical contraction 
7.47 (1.63-34.4) 
Rienstra et al, 
2014 (149) 
3217 10 years Soluble ST2 NA Incident AF No association 
Rosenberg et al, 
2014 (150) 
2935 8.8 years PIIINP NA Incident AF 0.85 (0.72-1.00) and 0.93 (0.88-
0.99) at the 10th and 25th 
percentiles, setting the median 
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as the reference, no association 
at the 75th and 90th percentiles  
Sasaki et al, 
2014 (76) 
113 13.8 (8.7–
19.9) months 
IBS AF catheter ablation AF recurrence 1.04 (1.01-1.07) 
Seitz et al, 2011 
(151) 
22 NA DE-MRI AF catheter ablation ‘Difficulty’ of AF 
ablation (time to 
terminate AF; 
radiofrequency duration 
until AF termination; 
complex fractionated 
atrial electrograms 
area/LA surface) 
Significant correlation between 
the fibrosis grade and the 
electrophysiological substrate 
indexes 
Wang et al, 2009 
(152) 
74 NA IBS CABG Postoperative AF Higher IBS in postoperative AF 
versus SR 
Wang et al, 2012 
(153) 
80 6 months Histology, TGF-β1 Modified MAZE 
procedure, mitral valve 
AF recurrence, absence 
of atrial mechanical 
Increasing recurrence rate with 
increasing TGF-β1 expression 
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surgery contraction 
Wu et al, 2013 
(124) 
200 10.9±7.4 
months 
TGF-β1 AF catheter ablation AF recurrence 1.11 (1.01–1.22) 
* Significant association in univariate analysis only, not significant after adjustment for traditional clinical AF risk factors 
AF, atrial fibrillation; CABG, coronary artery bypass graft; CI, confidence interval; DE-MRI, delayed enhancement magnetic resonance 
imaging; HR, hazard ratio; IBS, integrated backscatter; NA, not available; OR, odds ratio; other abbreviations as in Table 1. 
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Figure 1. Schematic overview of the TGF-β1 signaling pathway in cardiac fibrosis. 
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COL1A1, gene encoding α1 type I collagen; COL1A2, gene encoding α2 type I collagen; 
COL3A1, gene encoding α1 type III collagen; CTGF, connective tissue growth factor; ECM, 
extracellular matrix; ERK, extracellular signal-regulated kinase; JNK, c-jun N-terminal 
kinase; LOX, lysyl oxidase; LTBP, latent TGF-β1 binding protein; MMP, matrix 
metalloproteinase; p38, protein 38 (member of MAPK, mitogen-activated protein kinases); 
SAPK, stress-activated protein kinase; Smad, transcriptional factor (see Table 1); TAK1, 
TGF-β1 activated kinase 1; TβRI, type I TGF-β1 receptor; TβRII, type II TGF-β1 receptor; 
TGF-β1, transforming growth factor β1; TIMP, tissue inhibitor of MMP. 
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Figure 2. Involvement of inflammation pathways in cardiac fibrosis 
AF, atrial fibrillation; ECM, extracellular matrix; HF, heart failure; IL, interleukin; MPO, myeloperoxidase; NFκB, nuclear factor kappa B; 
PDGF, platelet derived growth factor; RAAS, renin angiotensin aldosterone system; TNFα, tumor necrosis factor α 
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Figure 3. Oxidative stress in cardiac fibrosis 
NADPH, reduced nicotinamide-adenine dinucleotide phosphate; MAPK, mitogen-activated protein kinase; p38, protein 38 (member of MAPK, 
mitogen-activated protein kinases); ROS, reactive oxygen species; other abbreviations as in Figures 1 to 2.  
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Figure 4. Cardiomyocytes, cardiac fibroblasts and myofibroblasts crosstalk and 
paracrine factors mediating profibrotic and antifibrotic effects 
Aldo, aldosterone; Ang II, angiotensin II; ET-1, endothelin-1; FGF-2, fibroblast growth facor 
2; IL, interleukin; miR, microRNA; other abbreviations as in Figures 1 to 3. 
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